Search clinical trials for: Envafolimab combined with recombinant human endostatin and first-line chemotherapy

Total 90 results

Fudan University

Not yet recruiting

Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma

Advanced Mucosal Melanoma
Anhui Chest Hospital

Not yet recruiting

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Chongqing University Cancer Hospital

Not yet recruiting

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Nasopharyngeal Carcinoma
Second Xiangya Hospital of Central South University

Enrolling by invitation

A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC

Non-small Cell Lung Cancer

China
Qilu Hospital of Shandong University

Recruiting

Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC

Squamous Non-small Cell Lung Cancer

China
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer

Colorectal Neoplasms
Sun Yan
Peking University; Peking University Cancer Hospital & Institute

Unknown

Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors (SLICER)

Head and Neck Neoplasms

China
Simcere Pharmaceutical Co., Ltd
Daping Hospital and the Research Institute of Surgery of the Third Military...

Unknown

Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Hairong Liu

Not yet recruiting

Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Efficacy and Safety
The First Affiliated Hospital of Xinxiang Medical...

Not yet recruiting

Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy

Locally Advanced Squamous Non-small Cell Lung Cancer
Hebei Medical University

Recruiting

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

Leptomeningeal Metastasis | Immune Checkpoint Inhibitor | Endostatin

China
Nanjing First Hospital, Nanjing Medical University

Recruiting

Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

Gastrointestinal Neoplasms

China
Peking University Third Hospital

Not yet recruiting

Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer

Cervical Cancer
Yong Chen

Recruiting

Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

Other Disorders of Soft Tissues

China
Zhejiang Cancer Hospital

Unknown

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Breast Cancer

China
Shandong University
The First Affiliated Hospital of Anhui Medical University; The Affiliated Hospital... and other collaborators

Completed

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Purpura | Idiopathic Thrombocytopenic Purpura

China
Ming Hou
Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaborators

Completed

Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
Fujian Cancer Hospital

Recruiting

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

Untreated Advanced Non-small Cell Lung Cancer

China
Shandong University
China Medical University, China; The Affiliated Hospital of the Chinese Academy... and other collaborators

Withdrawn

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
Sichuan Provincial People's Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer. (EXECC)

Quality of Life

China
Shanghai Chest Hospital
Wuhan University

Not yet recruiting

Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC (RELIEF)

Lung Cancer
Sun Yat-sen University

Not yet recruiting

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases (SUPER BRAIN)

Bevacizumab | Brain Metastases | Immunotherapy | Non-small Cell Lung Cancer Stage II

China
Shandong University
China Medical University, China; The Affiliated Hospital of the Chinese Academy... and other collaborators

Completed

rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP

Purpura | Idiopathic Thrombocytopenic Purpura

China
Simcere Pharmaceutical Co., Ltd

Unknown

A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

China
Anhui Provincial Hospital

Unknown

Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

Adenocarcinoma of Lung

China
Dragonboat Biopharmaceutical Company Limited
West China Hospital

Recruiting

An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Shanghai Chest Hospital

Completed

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Lung Adenocarcinoma | EGFR Activating Mutation
Qianfoshan Hospital

Recruiting

First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial (FTANLCNDG)

Non-Small-Cell Lung Cancer

China
Qianfoshan Hospital

Recruiting

Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion

Non Small Cell Lung Cancer

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
G1 Therapeutics, Inc.

Completed

Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin Combined With Etoposide or Topotecan

Extensive-stage Small-cell Lung Cancer

China
Thomas Jefferson University
Janssen Scientific Affairs, LLC

Active, not recruiting

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Peking University Third Hospital

Recruiting

Sequential Therapy of TCM Herbs to Improve the Success Rate of IVF-ET in Diminished Ovarian Reserve Patients

Infertility, Female

China
Peking University Third Hospital

Not yet recruiting

Traditional Chinese Medicine Herbs in the Freeze-all IVF Cycle

Infertility, Female
Sun Yat-sen University

Recruiting

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Hepatocellular Carcinoma

China
Immune System Key Ltd

Withdrawn

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Triple Negative Breast Cancer | Metastatic Ovarian Cancer

Israel
Northwestern University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Atypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial Meningioma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Neoplasm

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage... and other conditions

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

Recurrent Brain Neoplasm

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Neuroendocrine Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

Glioma | Glioblastoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Vaginal Squamous Cell Carcinoma, Not Otherwise Specified | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Recurrent Merkel Cell Carcinoma | Recurrent Nasopharynx Carcinoma | Appendix Adenocarcinoma and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal Carcinoma

United States

Search clinical trials for: Envafolimab combined with recombinant human endostatin and first-line chemotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations